Lyell Income Before Tax vs Total Operating Expenses Analysis

LYEL Stock  USD 1.17  0.04  3.31%   
Lyell Immunopharma financial indicator trend analysis is infinitely more than just investigating Lyell Immunopharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lyell Immunopharma is a good investment. Please check the relationship between Lyell Immunopharma Income Before Tax and its Total Operating Expenses accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.

Income Before Tax vs Total Operating Expenses

Income Before Tax vs Total Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lyell Immunopharma Income Before Tax account and Total Operating Expenses. At this time, the significance of the direction appears to have pay attention.
The correlation between Lyell Immunopharma's Income Before Tax and Total Operating Expenses is -0.9. Overlapping area represents the amount of variation of Income Before Tax that can explain the historical movement of Total Operating Expenses in the same time period over historical financial statements of Lyell Immunopharma, assuming nothing else is changed. The correlation between historical values of Lyell Immunopharma's Income Before Tax and Total Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Before Tax of Lyell Immunopharma are associated (or correlated) with its Total Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Operating Expenses has no effect on the direction of Income Before Tax i.e., Lyell Immunopharma's Income Before Tax and Total Operating Expenses go up and down completely randomly.

Correlation Coefficient

-0.9
Relationship DirectionNegative 
Relationship StrengthSignificant

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Lyell Immunopharma income statement and is an important metric when analyzing Lyell Immunopharma profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.
Most indicators from Lyell Immunopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lyell Immunopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.At this time, Lyell Immunopharma's Selling General Administrative is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 541.02 this year, although the value of Issuance Of Capital Stock will most likely fall to 0.00.
 2021 2022 2023 2024 (projected)
Interest Income1.2M7.1M23.5M24.6M
Net Interest Income1.2M7.1M23.5M24.6M

Lyell Immunopharma fundamental ratios Correlations

0.940.330.950.99-0.60.760.950.5-0.67-0.760.490.870.980.810.680.960.80.280.6-0.210.940.890.610.130.78
0.940.070.910.97-0.80.871.00.75-0.51-0.910.50.760.870.940.880.970.910.350.71-0.51.00.930.8-0.170.86
0.330.070.370.240.54-0.220.1-0.53-0.70.30.30.510.47-0.22-0.280.14-0.22-0.54-0.250.80.050.03-0.530.95-0.06
0.950.910.370.94-0.550.630.910.45-0.58-0.720.720.790.910.730.640.950.70.30.66-0.170.890.750.540.190.6
0.990.970.240.94-0.680.820.980.6-0.62-0.820.470.840.950.870.760.970.850.30.65-0.320.970.930.690.010.83
-0.6-0.80.54-0.55-0.68-0.86-0.78-0.950.010.95-0.24-0.34-0.46-0.93-0.91-0.74-0.9-0.63-0.750.9-0.81-0.76-1.00.71-0.75
0.760.87-0.220.630.82-0.860.860.77-0.47-0.940.050.710.720.920.880.760.990.490.46-0.640.890.940.89-0.430.95
0.951.00.10.910.98-0.780.860.73-0.52-0.90.490.770.890.940.870.970.90.320.7-0.481.00.940.79-0.140.86
0.50.75-0.530.450.6-0.950.770.730.1-0.860.260.20.350.910.930.660.80.370.76-0.930.760.710.93-0.750.72
-0.67-0.51-0.7-0.58-0.620.01-0.47-0.520.10.29-0.06-0.93-0.81-0.29-0.24-0.45-0.440.120.18-0.35-0.51-0.58-0.05-0.56-0.56
-0.76-0.910.3-0.72-0.820.95-0.94-0.9-0.860.29-0.33-0.59-0.66-0.95-0.95-0.83-0.97-0.59-0.670.75-0.92-0.86-0.960.5-0.84
0.490.50.30.720.47-0.240.050.490.26-0.06-0.330.210.40.320.330.590.170.090.65-0.060.460.160.190.220.0
0.870.760.510.790.84-0.340.710.770.2-0.93-0.590.210.940.580.510.720.70.150.140.060.770.790.380.330.74
0.980.870.470.910.95-0.460.720.890.35-0.81-0.660.40.940.710.580.880.740.180.43-0.050.870.860.480.270.76
0.810.94-0.220.730.87-0.930.920.940.91-0.29-0.950.320.580.710.960.880.950.410.74-0.740.950.930.93-0.460.9
0.680.88-0.280.640.76-0.910.880.870.93-0.24-0.950.330.510.580.960.760.910.330.64-0.790.90.840.91-0.540.85
0.960.970.140.950.97-0.740.760.970.66-0.45-0.830.590.720.880.880.760.820.40.79-0.40.960.860.73-0.060.74
0.80.91-0.220.70.85-0.90.990.90.8-0.44-0.970.170.70.740.950.910.820.530.55-0.670.930.930.92-0.430.93
0.280.35-0.540.30.3-0.630.490.320.370.12-0.590.090.150.180.410.330.40.530.43-0.50.350.270.64-0.470.22
0.60.71-0.250.660.65-0.750.460.70.760.18-0.670.650.140.430.740.640.790.550.43-0.620.690.530.71-0.380.4
-0.21-0.50.8-0.17-0.320.9-0.64-0.48-0.93-0.350.75-0.060.06-0.05-0.74-0.79-0.4-0.67-0.5-0.62-0.52-0.49-0.880.93-0.54
0.941.00.050.890.97-0.810.891.00.76-0.51-0.920.460.770.870.950.90.960.930.350.69-0.520.940.82-0.190.88
0.890.930.030.750.93-0.760.940.940.71-0.58-0.860.160.790.860.930.840.860.930.270.53-0.490.940.78-0.210.97
0.610.8-0.530.540.69-1.00.890.790.93-0.05-0.960.190.380.480.930.910.730.920.640.71-0.880.820.78-0.70.78
0.13-0.170.950.190.010.71-0.43-0.14-0.75-0.560.50.220.330.27-0.46-0.54-0.06-0.43-0.47-0.380.93-0.19-0.21-0.7-0.31
0.780.86-0.060.60.83-0.750.950.860.72-0.56-0.840.00.740.760.90.850.740.930.220.4-0.540.880.970.78-0.31
Click cells to compare fundamentals

Lyell Immunopharma Account Relationship Matchups

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Lyell Immunopharma is a strong investment it is important to analyze Lyell Immunopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lyell Immunopharma's future performance. For an informed investment choice regarding Lyell Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.
You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.79)
Quarterly Revenue Growth
0.36
Return On Assets
(0.19)
Return On Equity
(0.33)
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.